{"nctId":"NCT00648908","briefTitle":"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial","startDateStruct":{"date":"2006-06"},"conditions":["Multiple Sclerosis"],"count":269,"armGroups":[],"interventions":[{"name":"Fampridine-SR","otherNames":["4-aminopyridine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* subject must have been previously enrolled in Acorda Therapeutics MS-F203 study for multiple sclerosis and received either Fampridine-SR or placebo\n* subject is a man or woman with clinical definite multiple sclerosis as defined by McDonald (McDonald WI, et al. Recommended Diagnostic Criteria for Multiple Sclerosis; Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis; Annals of Neurology. 2001; 50: 121-127)\n* subject must be at least 18 years of age. Any subject who is now over the age of 70 must be in good overall health in the judgment of the Investigator\n* subject must be of adequate cognitive function, as judged by the Investigator, to understand and sign the IRB/REB-approved informed consent form prior to the performance of any study-specific procedures and is willing to comply with the required scheduling and assessments of the protocol\n* subjects who are women of childbearing potential, regardless of sexual activity, must have a negative urine pregnancy test at the Screening Visit.\n\nExclusion Criteria:\n\n* women who are either pregnant or breastfeeding, and women of childbearing potential (defined as not surgically sterile or at least two years post menopausal) who are engaged in active heterosexual relations and, are not using one of the following birth control methods: tubal ligation, implantable contraception device, oral, patch, injectable or transdermal contraceptive, barrier method or sexual activity restricted to vasectomized partner.\n* subject discontinued prematurely from the MS-F203 study\n* subject has a history of seizures or has evidence of past, or possible, epileptiform activity on an EEG\n* subject has either a clinically significant abnormal ECG or laboratory value(s) at the Screening visit, as judged by the Investigator that would preclude entry into the study. ECG and laboratory results from Visit 6 or repeat results from Visit 7 of the MS-F203 study may be used as the baseline for the current study\n* subject has angina, uncontrolled hypertension, clinically significant cardiac arrhythmias, or any other clinically significant cardiovascular abnormality, as judged by the Investigator\n* subject has a known allergy to pyridine-containing substances or any of the inactive ingredients of the Fampridine-SR tablet (hydroxypropyl methylcellulose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, opadry white (tablet film coating))\n* subject has received an investigational drug, except for Fampridine-SR or matching placebo under protocol MS-F203, within 30 days of the Screening Visit. Subject is scheduled to enroll in an investigational drug trial at any time during this study.\n* subject has a history of drug or alcohol abuse within the past year","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Summary of Treatment Emergent Adverse Events (TEAE).","description":"All adverse events reported were treatment emergent. Therefore, events that had a date of onset, or worsening, on or after the start of the open-label drug and up to 14 days after the last dose (for non-serious events) or up to 30 days after the last dose (for SAEs) were summarized. Any abnormal clinically significant changes in physical examination, medical history, clinical laboratory testing, 12-lead ECG, and standard EEG testing were captured as adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"264","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null}]}]}]},{"type":"SECONDARY","title":"Timed 25 Foot Walk (T25FW)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.35","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.28","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":"1.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.56","spread":"0.97"}]}]}]},{"type":"SECONDARY","title":"Subject Global Impression (SGI)","description":"Patients asked to complete a Subject Impression questionnaire rating his/her impression of the effects of study drug during the preceding week, specifically in regards to signs and symptoms associated with Multiple Sclerosis (MS).\n\nFor the SGI, the potential responses to the effects of the investigational drug during the preceding week were 1=terrible, 2=unhappy, 3=mostly dissatisfied, 4=neutral/ mixed, 5=mostly satisfied, 6=pleased, and 7=delighted.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.85","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.79","spread":"1.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.86","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.80","spread":"1.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.95","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.03","spread":"1.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.14","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.09","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.13","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.16","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.20","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.46","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Clinician Global Impression of Change (CGIC)","description":"Investigator's overall impression of the patients neurological status and general state of health related to his/her participation in the study; specifically signs and symptoms associated with MS.\n\nThe potential responses were 1=very much improved, 2=much improved, 3=somewhat improved, 4=no change, 5=somewhat worse, 6=much worse, and 7=very much worse.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.38","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.56","spread":"0.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.55","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.63","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.66","spread":"0.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.59","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.69","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.85","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.93","spread":"1.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.97","spread":"1.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.39","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Expanded Disability Status Scale (EDSS)","description":"Each patient, based on their baseline neurological exam, are scored according to the EDSS\n\nThe EDSS was used to grade patient disability on a scale from 0.0 (normal neurological exam) to 10.0 (death) at the Screening Visit, Visit 6, and Final Visit or Early Termination Visit if applicable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.78","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.95","spread":"1.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.16","spread":"0.94"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":94,"n":269},"commonTop":["Urinary Tract Infection","Fall","Multiple Sclerosis Relapse","Arthralgia","Oedema Peripheral"]}}}